Amsterdam, Netherlands

Bas Teusink

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Glaxosmithkline Biologicals Sa. Active years: 2017.


% Patents Active = 100.0


 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Bas Teusink: Innovator in Biotechnological Media

Introduction

Bas Teusink is a notable inventor based in Amsterdam, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of chemically defined media for industrial-scale culture of various species. His innovative work has implications for the advancement of biological research and applications.

Latest Patents

Teusink holds a patent for his invention titled "Chemically defined media for the industrial-scale culture of species." This patent represents a crucial step in enhancing the efficiency and effectiveness of biotechnological processes. He has 1 patent to his name, showcasing his commitment to innovation in this field.

Career Highlights

Bas Teusink is currently employed at GlaxoSmithKline Biologicals SA, a leading company in the pharmaceutical and biotechnology sectors. His role at the company allows him to apply his expertise in developing solutions that can benefit various biological applications.

Collaborations

Throughout his career, Teusink has collaborated with esteemed colleagues, including Philippe Marc, Helene Dehottay, and Philippe Goffin. These collaborations have fostered a productive environment for innovation and research.

Conclusion

In summary, Bas Teusink is a prominent inventor whose work in biotechnological media has the potential to transform industrial-scale biological processes. His contributions are vital to the ongoing advancements in biotechnology and its applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…